Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Kunath, Frank ^a,b,c   Grobe, Henrik R ^b   Rücker, Gerta ^b   Motschall, Edith ^b   Antes, Gerd ^b   Dahm, Philipp ^d,e   Wullich, Bernd ^a,c   Meerpohl, Joerg J ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Deutsche Gesellschaft für Pädiatrische Infektiologie e V   (Germany)

^d UNIVERSITY OF FLORIDA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST; TRIPTORELIN; ANILIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FLUTAMIDE; GONADORELIN; GOSERELIN; LEUPRORELIN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ADVANCED CANCER; ARTHRALGIA; ASTHENIA; BACKACHE; BLEEDING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CASTRATION; DIARRHEA; DRUG EFFECT; ENZYME BLOOD LEVEL; EVIDENCE BASED MEDICINE; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; INTERMETHOD COMPARISON; MASTALGIA; NOCTURIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TREATMENT FAILURE; DISEASE COURSE; MALE; MEDICATION COMPLIANCE; META ANALYSIS; MORTALITY; ORCHIECTOMY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MEDICATION ADHERENCE; NITRILES; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOSYL COMPOUNDS; TRIPTORELIN PAMOATE;

EID: 84933684567     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009266.pub2     Document Type: Review

References (191)

1. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, et al.Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. European Urology 1997;32(4):391-5; discussion 5-6.
2. Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Nihoyannopoulos P, Kemp M, et al.Anti-androgens increase N-Terminal pro-BNP in men with prostate cancer. Clinical Endocrinology 2008;68:59-65.
3. Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. Journal of Andrology 2009;30(4):410-5.
4. Sciarra A, Di Silverio F. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology 2004;63(3):523-7.
5. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology 2004;171(6 Pt 1):2272-6.
6. Pirl WF, Greer JA, Goode M, Smith MR. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho-oncology 2008;17(2):148-53.
7. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology 2004;22(13):2546-53.
8. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996;47(1A Suppl):38-43; discussion 48-53.
9. Iversen P, Tveter K, Varenhorst E. Randomised study of casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology 1996;30(2):93-8.
10. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996;47(1A Suppl):38-43; discussion 48-53.
11. Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F. A randomized comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. European Urology 1995;28(3):215-22.
12. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996;47(1A Suppl):38-43; discussion 48-53.
13. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995;46(6):849-55.
14. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, et al.Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51(3):389-96.
15. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al.Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology 2000;164(5):1579-82.
16. Tyrrell CJ, Blake GM, Iversen P, Kaisary AV, Melezinek I. The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology 2003;21(1):37-42.
17. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al.A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology 1998;33(5):447-56.
18. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, et al.Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51(3):389-96.
19. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al.Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Journal of Urology 2000;164(5):1579-82.
20. Tyrrell CJ, Blake GM, Iversen P, Kaisary AV, Melezinek I. The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study. World Journal of Urology 2003;21(1):37-42.
21. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al.A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology 1998;33(5):447-56.
22. Tyrrell CJ, Iversen P, Tammela T, Anderson J, Bjork T, Kaisary AV, et al.Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU International 2005;96(3):563-72. Erratum in: BJU International 2006;98(3):572.
23. Akaza H, Usami M, Kotake T, Koiso K, Aso Y. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group. Japanese Journal of Clinical Oncology 1993;23(3):178-85.
24. Akaza H, Homma Y, Okada K, Yokoyama M, Usami M, Hirao Y, et al.A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up. BJU International 2003;91(1):33-6.
25. Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, et al.Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. American Journal of Therapeutics 2006;13(4):291-7.
26. Aso Y, Akaza H, Koiso K, Kumamoto Y, Kawai T, Origasa S, et al.Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica 1993;39(4):381-9.
27. Aso Y, Akaza H, Kameyama S, Koiso K, Koyanagi T, Kawai T, et al.Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study. Hinyokika Kiyo. Acta Urologica Japonica 1993;39(4):391-403.
28. Auvinen A, Hakama M, Ala-Opas M, Vornanen T, Leppilahti M, Salminen P, et al.A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen. BJU International 2004;93(1):52-6; discussion 6.
29. Ayub M, Levell MJ. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue. Clinical Endocrinology 1990;32(3):329-39.
30. Blackledge GR. High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology 1996;47(1A Suppl):44-7; discussion 8-53.
31. Boccardo F, Barichello M, Battaglia M, Carmignani G, Comeri G, Ferraris V, et al.Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. European Urology 2002;42(5):481-90.
32. Boccardo F, Rubagotti A, Borichello M, Battaglia M, Carmignani G, Comeri G, et al.Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Journal of Clinical Oncology 1999;17(7):2027-38.
33. Bono AV, Mazzucchelli R, Ferrari I, Lopez-Beltran A, Galosi AB, Cheng L, et al.Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. Journal of Clinical Pathology 2007;60(4):443-6.
34. Bruun E, Frimodt-Møller C. The effect of buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. Scandinavian Journal of Urology and Nephrology 1996;30(4):291-7.
35. Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, et al.Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. Journal of Clinical Oncology 1996;14(8):2250-7.
36. Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Casodex (ICI 176, 334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. European Urology 1994;26 Suppl 1:10-4.
37. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, Denis L. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. European Urology 1990;18 Suppl 3:10-7.
38. Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, et al.Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer and Prostatic Diseases 2012;15(4):346-52.
39. Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, et al.Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. Journal of Clinical Oncology 1997;15(4):1470-7.
40. Decensi A, Zanardi S, Puntoni M, Bandelloni R, Branchi D, Argusti A, et al.Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy. Journal of Clinical Oncology 2007;25(18 Suppl):1500.
41. Zanardi S, Puntoni M, Maffezzini M, Bandelloni R, Mori M, Argusti A, et al.Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies. Cancer Prevention Research (Philadelphia, Pa.) 2009;2(4):377-84.
42. Ekwueme K, Parr N. Bicalutamide monotherapy in osteoporotic men requiring hormone manipulation for advanced prostate cancer: 12 year outcomes from a 'step up' regime. Journal of Urology 2012;187(4 Suppl):e383.
43. Fourcade RO, Richaud P, Brune D, Colombel P, Sarramon JP, Fournier G, et al.Effect of bicalutamide 150 mg, after 3 years of median follow-up, in non-metastatic prostatic cancer [Effet du bicalutamide 150 mg, à trois ans de suivi médian, dans le cancer de la prostate non métastatique]. Progres en Urologie 2003;13(3):430-9.
44. Fourcade RO, Richaud P, Coloby P, Malavaud B, Group des investigateuers français du programme EPC. Role of 150 mg bicalutamide in the treatment of prostate cancer: analysis of the EPC (early prostate cancer) program [Le bicalutamide 150 mg dans le traitement du cancer de la prostate localement avancé: des résultats à la pratique: Place du bicalutamide 150 mg dans le traitement du cancer de la prostate: hème analyse du programme EPC (Early Prostate Cancer)]. Progres en Urologie 2007;17(4 Suppl 1):891-910.
45. Iversen P, Johansson J-E, Lodding P, Lukkarinen O, Lundmo PI, Klarskov P, et al.Efficacy and tolerability of bicalutamide in early non-metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG-6) of the early prostate cancer programme. Meeting abstract of the 21st annual European Association of Urology Congress. 2006. www.uroweb.org/index.php?id=108&AID=9715.
46. Iversen P, Johansson JE, Lodding P, Kylmala T, Lundmo P, Klarskov P, et al.Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scandinavian Journal of Urology and Nephrology 2006;40(6):441-52.
47. Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, et al.Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology 2004;172(5 Pt 1):1871-6.
48. Iversen P, McLeod D, See W, Wirth M, Morris T, Morris C, et al.Bicalutamide 150 mg in addition to watchful waiting in patients with early non-metastatic prostate cancer: updated analysis at a median 5.4 years follow-up. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&AID=758.
49. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU International 2010;105(8):1074-81.
50. Iversen P, Roder MA. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Review of Anticancer Therapy 2008;8(3):361-9.
51. Iversen P, Tammela TLJ, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, et al.A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer - First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology 2002;42(3):204-11.
52. Iversen P, Wirth MP, See WA II, McLeod DG, Morris T, Armstrong J, et al.The influence of nodal status on progression outcomes in patients with prostate cancer: data from the Early Prostate Cancer program at 7.4 years. Journal of Clinical Oncology 2006;24(18 Suppl):4628.
53. Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, et al.Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology 2004;63(5):928-33.
54. McLeod D, Iversen P, See W, Wirth M, Carroll K, Morris C, et al.Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&AID=752.
55. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU International 2006;97(2):247-54.
56. McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, et al.The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. Journal of Urology 2006;176(1):75-80.
57. See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology 2003;44(5):512-8.
58. See WA, McLeod D, Iversen P, Wirth M. The bicalutamide Early Prostate Cancer Program: demography. Urologic Oncology 2001;6(2):43-7.
59. See WA, McLeod DG, Iversen P, Wirth MP, Armstrong J, Navani S. Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: results from Early Prostate Cancer program. Journal of Clinical Oncology 2006;24(18 Suppl):4624.
60. See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology 2006;132 Suppl 1:S7-16.
61. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al.Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. Journal of Urology 2002;168(2):429-35.
62. Tyrrell C. Immediate treatment with bicalutamide, 150 mg/d, following radiotherapy in localized or locally advanced prostate cancer. Reviews in Urology 2004;6 Suppl 2:S29-36.
63. Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, et al.Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology 2005;76(1):4-10.
64. Wirth M, Hakenberg O, Froehner M. Adjuvant hormonal treatment - the Bicalutamide Early Prostate Cancer Program. Frontiers of Radiation Therapy and Oncology 2008;41:39-48.
65. Wirth M, Iversen P, McLeod D, See W, Morris C, Morris T, et al.Bicalutamide 150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: analysis at a median follow-up of 5.4 years. Meeting abstract of the XIXth European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&AID=560.
66. Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace D, et al.Adjuvant therapy with bicalutamide 150 mg versus standard care alone: third analysis results from Trial 24 of the Early Prostate Cancer programme. Meeting abstract of the XIXth annual European Association of Urology Congress. 2004. www.uroweb.org/index.php?id=108&AID=9672.
67. Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM, et al.Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer and Prostatic Diseases 2005;8(2):194-200.
68. Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM, et al.Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer and Prostatic Diseases 2007;10(1):87-93.
69. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sánchez-Chapado M, Ramon J, et al.Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001;58(2):146-51.
70. Wirth MP, Froehner M. Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program. Oncology 2003;65 Suppl 1:1-4.
71. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Armstrong J. Delaying metastatic disease progression in locally advanced disease - results from the Early Prostate Cancer program at a median follow-up of 7.4 years. Journal of Clinical Oncology 2006;24(18 Suppl):4629.
72. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4 years. Journal of Urology 2004;172(5 Pt 1):1865-70.
73. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. Journal of Urology 1993;150(1):90-4.
74. Eri LM, Svindland A, Tveter KJ. The effect of bicalutamide on prostate histology. Prostate 2001;46(4):275-80.
75. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Ricevuto E, et al.In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate 2007;67(12):1255-64.
76. Gravina GL, Festuccia C, Galatioto GP, Muzi P, Angelucci A, Ronchi P, et al.Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology 2007;70(4):728-33.
77. Henderson A, Langley SEM, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clinical Oncology 2003;15(6):318-21.
78. Iida K. Monotherapy versus combined androgen blockade for advanced/metastatic prostate cancer. Gan to Kagaku Ryoho. Cancer & Chemotherapy 2011;38(13):2553-7.
79. Jacobo E, Schmidt JD, Weinstein SH, Flocks RH. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 1976;8(3):231-3.
80. Johansson J-E, Lingårdh G, Andersson S-O, Zador G, Beckman K-W. Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 1987;29(1):55-9.
81. Johansson JE, Andersson SO, Beckman KW, Zador G. Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate. American Journal of Clinical Oncology 1988;11 Suppl 2:S183-6.
82. Jones HB, Betton GR, Bowdler AL, McFarquhar RL, Middleton BJ, Lunglmayr G. Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176, 334) or bilateral orchidectomy. Urological Research 1994;22(3):191-5.
83. Kaisary AV. Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate. Supplement 1994;5:27-33.
84. Kariakin OB, Sviridova TV, Tsodikova LB, Grishin GN, Sergeeva TN, Perekhrest MA, et al.Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer. Urologiia (Moscow, Russia: 1999) 2001;4:26-9.
85. Kasimis B, Wilding G, Kreis W, Feuerman M, Chang V, Hwang S, et al.Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D-2) prostate cancer. Cancer Investigation 2000;18(7):602-8.
86. Kotake T, Usami M, Isaka S, Shimazaki J, Oishi K, Yoshida O, et al.Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica 1996;42(2):143-53.
87. Kotake T, Usami M, Isaka S, Shimazaki J, Nakano E, Okuyama A, et al.Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica 1996;42(2):157-68.
88. Kulkarni JN, Gupta R. Early report of randomized double blind clinical trial of hormonal therapy of carcinoma of prostate (CAP) stage D2. Indian Journal of Urology 2003;19(2):135-9.
89. Lazzaro C, Bartoletti R, Guazzoni G, Orestano F, Pappagallo GL, Prezioso D, et al.Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS). Archivio Italiano di Urologia, Andrologia 2007;79(3):104-7.
90. Lee S, Chung YJ, Kim BH, Shim JH, Yoon SH, Shin SG, et al.Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. Clinical Therapeutics 2009;31(12):3000-8.
91. Lee S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. Clinical Therapeutics 2010;32(14):2496-501.
92. Lehmusvaara S, Erkkila T, Urbanucci A, Waltering K, Seppala J, Larjo A, et al.Chemical castration and anti-androgens induce differential gene expression in prostate cancer. Journal of Pathology 2012;227(3):336-45.
93. Lin YH, Chen CL, Hou CP, Chang PL, Tsui KH. A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. Acta Pharmacologica Sinica 2011;32(4):537-42.
94. Lissoni P, Malugani F, Casu M, Bukovec R, Egardi R, Bordin V, et al.Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients. Neuro Endocrinology Letters 2002;23(1):61-3.
95. Loran OB, Pushkar D, Kosko D, Bernikov AN. Bicalutamide monotherapy of patients with disseminated forms of prostatic cancer. Urologiia (Moscow, Russia: 1999) 2001;3:26-8.
96. Lund F, Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. British Journal of Urology 1988;61(2):140-2.
97. Lunglmayr G. Efficacy and tolerability of Casodex in patients with advanced prostate cancer. Anti-cancer Drugs 1995;6(4):508-13.
98. McGivern U, Mitchell DM, O'Hare J, Corey G, O'Sullivan JM. How does neoadjuvant bicalutamide 150 mg monotherapy compare to luteinising hormone-releasing hormone agonist (LHRHa) therapy in localized prostate cancer treated with radical prostatectomy? A case-matched comparison of PSA kinetics and biochemical outcome. Journal of Clinical Oncology 2011;29(7 Suppl):146.
99. McGivern U, Mitchell DM, McDowell C, O'Hare J, Corey G, O'Sullivan JM. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis. Clinical Genitourinary Cancer 2012;10(3):190-5.
100. Migliari R, Muscas G, Melis M, Garau M, Sorgia M, Scarpa M, et al.Monitoring of erection function in patients with prostatic carcinoma treated with Casodex. Archivio Italiano di Urologia, Nefrologia, Andrologia [Urological, Nephrological, and Andrological Sciences] 1991;63(1):155-61.
101. Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. Journal of Urology 1992;148(2 Pt 1):338-41.
102. Motofei IG, Rowland DL, Popa F, Kreienkamp D, Paunica S. Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal. BJU International 2011;108(1):110-5.
103. Murphy JC, Srinivas S, Terris MK. Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. Journal of Andrology 2004;25(4):630-4.
104. Newling DW. The use of flutamide as monotherapy in the treatment of advanced prostate cancer. Progress in Clinical and Biological Research 1989;303:117-21.
105. Noldus J, Ferrari M, Prestigicomo A, Stamey TA. Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer. Urology 1996;47(5):713-8.
106. Nyman CR, Andersen JT, Lodding P, Sandin T, Varenhorst E. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy. BJU International 2005;96(7):1014-8.
107. Oosterlinck W, Casselman J, Mattelaer J, Van Velthoven R, Kurjatkin O, Schulman C. Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients - a Belgian multicenter study of 905 patients. European Urology 1996;30(4):458-63.
108. Ostri P, Bonnesen T, Nilsson T, Frimodt-Moller C. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial. Urologia Internationalis 1991;46(2):167-71.
109. Petit JH, Gluck C, Kiger WS, Henry DL, Karasiewicz C, Talcott J, et al.Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity. Urologic Oncology 2008;26(4):372-7.
110. Prezioso D, Bartoletti R, Cecchi M, Cicalese V, Cunico SC, Damiano R, et al.Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study. Archivio Italiano di Urologia, Andrologia 2007;79(3):99-103.
111. Raina R, Pahalajani G, Agarwal A, Zippe C. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Asian Journal of Andrology 2007;9(2):253-8.
112. Raynaud JP. Antiandrogens in combination with LH-RH agonists in prostate cancer. American Journal of Clinical Oncology 1988;11 Suppl 2:S132-47.
113. Scattoni V, Montironi R, Mazzucchelli R, Freschi M, Nava L, Losa A, et al.Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU International 2006;98(1):54-8.
114. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al.Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Journal of Clinical Oncology 1997;15(8):2928-38.
115. Schröder FH, Collette L, de Reijke TM, Whelan P, members of the EORTC Genitourinary Group. Prostate cancer treated by anti-androgens: is sexual function preserved?. British Journal of Cancer 2000;82(2):283-90.
116. Schröder FH, Whelan P, Reijke TM, Kurth KH, Pavone-Macaluso J, Mattelaer J, et al.Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. European Urology 2004;45(4):457-64.
117. Sciarra A, Cardi A, Di Silverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urologia Internationalis 2004;72(2):91-8.
118. See WA. Bicalutamide adjuvant to radical prostatectomy. Reviews in Urology 2004;6 Suppl 2:S20-8.
119. Shipley WU, Hunt D, Lukka HR, Major P, Heney NM, Grignon D, et al.Initial report of RTOG 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease and elevated PSA levels. Journal of Clinical Oncology 2011;29(7 Suppl):1.
120. Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003;61(1):127-31.
121. Soloway MS, Schellhammer PF, Smith JA Jr, Chodak GW, Vogelzang NJ, Kennealey GT. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II non-comparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. Journal of Urology 1995;154(6):2110-4.
122. Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Kennealey GT. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Urology 1996;47(1 Suppl 1):33-7; discussion 48-53.
123. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. European Urology 1996;29(1):47-54.
124. Thrasher JB, Deeths J, Bennett C, Iyer P, Dineen MK, Zhai S, et al.Comparative study of the clinical efficacy of two dosing regimens of flutamide. Molecular Urology 2000;4(3):259-63; discussion 265.
125. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID, et al.Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. European Urology 1998;33(1):39-53.
126. Verhelst J, Denis L, Van Vliet P, Van Poppel H, Braeckman J, Van Cangh P, et al.Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clinical Endocrinology 1994;41(4):525-30.
127. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU International 2009;104(6):800-5.
128. Wadhwa V, Weston R, Parr NJ. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer. BJU International 2011;107(12):1923-9.
129. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, et al.Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. European Urology 2004;45(3):267-70; discussion 270.
130. Yoshimura K, Sumiyoshi Y, Hashimura T, Ueda T, Kamiryo Y, Yamamoto A, et al.Neoadjuvant flutamide monotherapy for locally confined prostate cancer. International Journal of Urology 2003;10(4):190-5.
131. Zanardi S, Puntoni M, Maffezzini M, Bandelloni R, Mori M, Argusti A, et al.Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies. Cancer Prevention Research (Philadelphia, Pa.) 2009;2(4):377-84.
132. Zhigang Z, Wenlu S. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. International Journal of Cancer. Journal International du Cancer 2008;122(4):864-70.
133. Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. European Urology 2005;48(6):900-5.
134. Akl EA, Briel M, You JJ, Sun X, Johnston BC, Busse JW, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ (Clinical Research Ed.) 2012;18(344):e2809.
135. Als-Nielsen B, Gluud LL, Gluud C. Methodological quality and treatment effects in randomized trials: a review of six empirical studies. Meeting abstract of the 12th Cochrane Colloquium, Ottawa (Canada). 2004. www.cochrane.org/events/colloquia.
136. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al.American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. Journal of Clinical Oncology 2004;22(14):2927-41.
137. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al.Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology 2007;25(12):1596-605.
138. Azzouni F, Mohler J. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment. Urology 2012;79(6):1197-205.
139. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, et al.Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Journal of Clinical Oncology 1999;17(7):2027-38.
140. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Annals of Oncology 2005;16(3):481-8.
141. Chou R, Aronson N, Atkins D, Ismaila AS, Santaguida P, Smith DH, et al.AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. Journal of Clinical Epidemiology 2010;63(5):502-12.
142. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. Journal of Urology 1997;157(2):439-44.
143. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008:243-96.
144. Dockery F, Bulpitt CJ, Agarwal S, Rajkumar C. Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness. Aging Male 2002;5(4):216-22.
145. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al.Guidelines on prostate cancer. European Association of Urology; 2013. www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf (accessed 30 August 2013).
146. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al.Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. European Urology 2008;54(4):816-23.
147. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al.Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. Journal of Clinical Oncology 2009;27(1):92-9.
148. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone A-M, et al.Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118(9):2338-66.
149. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58(6):579-88.
150. Gartlehner G. Assessment of adverse effects and applicability - two areas not (yet) covered adequately in Cochrane reports. Zeitschrift fur Evidenz, Fortbildung und Qualitat Im Gesundheitswesen 2008;102(8):497-502.
151. Gibbs SJ, Plowman PN. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Clinical Oncology 1996;8(6):346-52.
152. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr (accessed 8 April 2014).
153. Grundmark B, Garmo H, Zethelius B, Stattin P, Lambe M, Holmberg L. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. European Journal of Clinical Pharmacology 2012;68(12):1619-30.
154. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
155. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Constraints on publication rights in industry-initiated clinical trials. JAMA 2006;295(14):1645-6.
156. Hampson LA, Montie JE. Conflict of interest in urology. Journal of Urology 2012;187(6):1971-7.
157. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
158. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557-60.
159. Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Statistics in Medicine 2004;23(11):1663-82.
160. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
161. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
162. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
163. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Journal of Urology 2002;167(2 Pt 2):948-51.
164. Iversen P. Antiandrogen monotherapy: indications and results. Urology 2002;60(3 Suppl 1):64-71.
165. Kunath F, Keck B, Antes G, Wullich B, Meerpohl JJ. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Medicine 2012;10:96.
166. Meerpohl JJ, Wolff RF, Niemeyer CM, Antes G, von Elm E. Editorial policies of pediatric journals: survey of instructions for authors. Archives of Pediatrics & Adolescent Medicine 2010;164(3):268-72.
167. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
168. Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, et al.Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306(21):2359-66.
169. Okike K, Kocher MS, Mehlman CT, Bhandari M. Conflict of interest in orthopaedic research. An association between findings and funding in scientific presentations. Journal of Bone and Joint Surgery. American Volume 2007;89(3):608-13.
170. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
171. Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. International Journal of Epidemiology 2007;36(4):847-57.
172. Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat and per protocol analyses. Journal of Clinical Epidemiology 2007;60(7):663-9.
173. Ramm O, Brubaker L. Conflicts-of-interest disclosures at the 2010 AUGS Scientific Meeting. Female Pelvic Medicine & Reconstructive Surgery 2012;18(2):79-81.
174. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
175. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt TJ. Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Systematic Reviews 1999, Issue 2. [DOI: 10.1002/14651858.CD001526]
176. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. BMJ (Clinical Research Ed.) 1996;312(7033):742-4.
177. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
178. Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, et al.Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/technology Assessment (Summary) 1999; Vol. 4:1-246.
179. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al.Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Annals of Internal Medicine 2000;132(7):566-77.
180. Shah RV, Albert TJ, Bruegel-Sanchez V, Vaccaro AR, Hilibrand AS, Grauer JN. Industry support and correlation to study outcome for papers published in Spine. Spine 2005;30(9):1099-104.
181. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002;60(3 Suppl 1):79-85.
182. Sun X, Briel M, Busse JW, Akl EA, You JJ, Mejza F, et al.Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. Trials 2009;10:101.
183. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, et al.Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ (Clinical Research Ed.) 2012;344:e1553.
184. Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. International Journal of Epidemiology 2005;34(1):79-87.
185. Tyrrell CJ. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176, 334) as monotherapy for prostate cancer. International Casodex Investigators. European Urology 1994;26 Suppl 1:15-9.
186. Wang SS, Ou YC, Cheng CL, Dahm P. Evidence-based urology in practice: when to believe a subgroup analysis?. BJU International 2010;105(2):162-4.
187. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(22):3337-51.
188. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. European Urology 2007;51(2):306-14.
189. Wirth MP, Hakenberg OW, Froehner M. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program. Frontiers of Radiation Therapy and Oncology 2008;41:39-48.
190. Wood AM, White IR, Thompson SG. A review of published randomized controlled trials in major medical journals. Clinical Trials (London, England) 2004;1(4):368-76.
191. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5.